ilmscore | 3 Stocks With Better Fundamentals Than Their Valuation

3 Stocks With Better Fundamentals Than Their Valuation

Published: 2025-06-25
Status: Analyzed

Predictions from this Video

Total: 6
Correct: 0
Incorrect: 0
Pending: 6
Prediction
Topic
Status
Patent protection for Natco Pharma's flagship product 'Cheed' is expected to expire by the end of FY26 (March 2026).
"the patent protection of the company's flagship product Cheed will expire by the end of FY26."
NATCOPHARM
Pending
Following the patent expiry of 'Cheed', generic competitors are expected to enter the market and sharply drive down prices.
"When this happens, other generic competitors will enter the market and drive prices down sharply."
NATCOPHARM
Pending
Natco Pharma's management estimates a potential 20% decline in revenues and 30% decline in profits due to patent expiry.
"According to management estimates, this could lead to a 20% decline in revenues and a 30% decline in profits."
NATCOPHARM
Pending
Natco Pharma's new high-value product launches, Pristum and Semaglotite, could offset the revenue decline from the G Rev Limit patent expiry by the end of FY26.
"With two complexes and high value launches. Pristum and Semaglotite. By the end of FY26, this could offset the decline in G Rev Limit and boost revenue."
NATCOPHARM
Pending
Natco Pharma's management aims to close at least one acquisition in the current fiscal year (FY26) to support future growth.
"the management has indicated that the company is looking to close at least one acquisition this year which will support future growth."
NATCOPHARM
Pending
Natco Pharma is allocating ₹400 crore for next-generation R&D, focusing on small molecules, cell, and gene therapies.
"The company is allocating 400 CR for next-generation RADs ranging from small molecules to cell and gene therapies."
NATCOPHARM
Pending